Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology business, despite a fall in revenue.
Hutchmed is a Hong Kong-based biopharmaceutical company focused on the development and commercialisation of therapies and immunotherapies for the treatment of cancer and immunological diseases.
Hutchmed reported a 43% fall in revenue to $305.7 million for the six months that ended June 30 from $532.9 million a year before.
Within this, oncology/immunology consolidated revenue was $168.7 million for the half, down from $359.2 million a year prior. However, first-half oncology/immunology product revenue rose 59% to $127.8 million from $80.1 million year-on-year, while R&D revenue within the consolidated total was $40.8 million, down from $279.0 million.
Net income decreased by 85% to $26.2 million for the half from $169.5 million a year before.
Looking forward, Hutchmed said it remains on track to meet its full-year guidance for oncology/immunology.
Thanks to the rising product revenue, consolidated revenue for oncology/immunology is expected to be between $300 million to $400 million, with a 30% to 50% growth rate.
Chair Dan Eldar commented: ‘Hutchmed has delivered strong performance in the first half of this year. The team has made significant progress implementing our strategy in discovering and developing novel, effective medicines; conducting clinical trials in our home market and in the global markets; and rapidly advancing regulatory and commercial goals.’
Hutchmed shares were up 5.0% to 296.00 pence each in London on Wednesday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.